On August 14, 2025, Ambassador Cui Aimin visited Ribocure Pharmaceuticals and held discussions with CEO Gan Liming and others on China-Sweden cooperation in scientific and technological innovation as well as healthcare.

Ambassador Cui introduced China’s efforts to drive high-quality development through scientific and technological innovation and to advance the “Healthy China” initiative. He noted that China and Sweden enjoy a solid foundation and enormous potential for exchanges and cooperation in scientific and technological innovation as well as healthcare. He expressed the hope that the company would strengthen exchanges and cooperation with research institutions and enterprises from both China and Sweden in areas such as biopharmaceutical R&D and the diagnosis and treatment of major diseases, thereby injecting fresh impetus into China-Sweden innovation cooperation and making new contributions to the development of global public health.

CEO Gan outlined the company’s development history, business operations, and future strategies. He expressed willingness to continue cultivating the Swedish biopharmaceutical market, enhance innovative drug R&D, and tackle major diseases, so as to create highlights in China-Sweden cooperation and contribute to the improvement of human health and well-being.